Taysha Gene Therapies, Inc. - 8-K Filing
Taysha Gene Therapies announced completion of dosing for its REVEAL pivotal trial, which evaluated TSHA-102 in Rett syndrome patients. The company reported positive longer-term clinical data from Part A (N=12) showing all patients gained or regained at least one developmental milestone by 12 months post-treatment with no treatment-related serious adverse events. Topline results and FDA feedback on the Biologics License Application pathway are expected in early 2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TSHA